查尔斯河利用先进技术加速肿瘤药物的发现与开发-动脉网

Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development

PHARMA FOCUS ASIA 等信源发布 2025-04-23 15:09



可切换为仅中文







Charles River Laboratories International, Inc, ahead of the American Association for Cancer Research® (AACR) Annual Meeting in Chicago, IL, has announced updates to its comprehensive portfolio of products and services supporting the discovery and development of novel oncology drugs. Based solely on projected population growth, the number of cancer cases is predicted to increase to 35 million by 2050, and approximately 1 in 5 individuals will develop cancer in their lifetime..

查尔斯河实验室国际有限公司在美国芝加哥举行的美国癌症研究协会 (AACR) 年会之前宣布了对其全面的产品和服务组合进行更新，这些产品和服务支持新型肿瘤药物的发现和开发。仅根据预计的人口增长，到 2050 年，癌症病例的数量预计将增加到 3500 万，大约每 5 人中就有 1 人在其一生中会患上癌症。

“Having worked on over 80 percent of the FDA-approved cancer therapies over the last five years, Charles River has a well-established track record of delivering innovative solutions for oncology researchers,” said Julia Schueler, DVM, PhD, Therapeutic Area Lead, Oncology, Charles River. “We are consistently looking for ways to leverage new technologies and techniques to enhance our ability to deliver life-changing therapeutics to patients.”.

“过去五年中，查尔斯河实验室参与了超过80%的FDA批准的癌症治疗药物的工作，这为我们积累了为肿瘤学研究人员提供创新解决方案的良好记录，”查尔斯河实验室肿瘤学领域负责人朱莉娅·舒勒博士（Julia Schueler，DVM，PhD）表示。“我们一直在寻找利用新技术和方法来增强我们为患者提供改变生命的治疗药物的能力。”

Developing a Fully Human Platform

开发全人类平台

Across several modalities, Charles River is developing and implementing humanized platforms to promote a more effective, translatable way of identifying human-specific drug targets and disease mechanisms, as well as treatments for individual patients. These methodologies include:

跨多种模式，查尔斯河正在开发和实施人源化平台，以促进更有效、可转化的方式来识别人类特定的药物靶点和疾病机制，以及针对个体患者的治疗方法。这些方法包括：

3D Tumoroids

3D肿瘤类器官

Patient-derived xenograft (PDX) models are an increasingly common tool drug developers use when evaluating their new therapies, particularly immunotherapies. Charles River researchers have developed PDX-derived organoids, or tumoroids, which are self-organized 3D cell cultures that aim to mimic the structure, function, and cellular complexity of human organs, making them, in some ways, more translatable than animals..

患者来源的异种移植（PDX）模型是药物开发者在评估其新疗法，尤其是免疫疗法时使用的日益常见的工具。查尔斯河实验室的研究人员开发了PDX衍生的类器官或肿瘤类器官，这些是自组织的3D细胞培养物，旨在模拟人体器官的结构、功能和细胞复杂性，这在某些方面使它们比动物模型更具转化性。

Julia Schueler is presenting on PDX-derived breast cancer tumoroids on Sunday, April 27, 2025, at 2:00 p.m. and on establishing tumoroids from PDX tissue for in vitro applications on Tuesday, April 29, 2025, at 2:00 p.m.

朱莉娅·舒勒将于2025年4月27日星期日下午2点展示关于PDX衍生的乳腺癌肿瘤类器官的内容，并于2025年4月29日星期二下午2点展示关于从PDX组织建立用于体外应用的肿瘤类器官的内容。

2D Tumor Killing Assays

二维肿瘤杀伤实验

Charles River has a range of immune-mediated tumor-killing assays, including cytotoxic T-cell assays and natural killer (NK) cell assays. These assays are analyzed using flow cytometry and live cell imaging with IncuCyte. IncuCyte-based assays quantify the number of viable target cells and can be multiplexed with an apoptotic readout.

查尔斯河(Charles River)拥有多种免疫介导的肿瘤杀伤检测方法，包括细胞毒性T细胞检测和自然杀伤(NK)细胞检测。这些检测通过流式细胞术和使用IncuCyte的活细胞成像进行分析。基于IncuCyte的检测可以量化存活靶细胞的数量，并且可以与凋亡读数结合进行多重分析。

The selection of target and effector cells can be tailored to the anticipated mechanism of action by selecting from a panel of validated target cell lines..

通过从一组经验证的靶细胞系中进行选择，可以针对预期的作用机制定制靶细胞和效应细胞的选择。

Ina Rohleff is presenting a comparison of NK-92MI cell line vs. primary NK cells derived from peripheral mononuclear blood cells on Wednesday, April 30, 2025, at 9:00 a.m.

2025年4月30日，星期三上午9:00，罗勒夫·伊娜将展示NK-92MI细胞系与来源于外周单核血细胞的原代NK细胞的比较。

Tumor Microenvironment

肿瘤微环境

Leveraging knowledge of the tumor microenvironment (TME), Charles River is able to target different components of the TME that promote tumor growth and metastasis through anti-tumor immune suppression.

利用对肿瘤微环境（TME）的了解，Charles River 能够通过抗肿瘤免疫抑制来靶向 TME 中促进肿瘤生长和转移的不同成分。

Louise Brackenbury is presenting on leveraging the tumor microenvironment for candidate vaccine screening on Tuesday, April 29, 2025, at 2:00 p.m.

路易丝·布拉肯伯里将于2025年4月29日星期二下午2点介绍利用肿瘤微环境进行候选疫苗筛选的相关内容。

Through a partnership with Cypre, Charles River clients can access Cypre's 3D tumor models to predict therapeutic efficacy and mechanism of action in an accurate tumor microenvironment model. Utilizing Cypre’s patented 3D hydrogel technology and proprietary methods that synergize with Charles River’s PDX tumor model collection, the platform recreates the tumor microenvironment and enables predictive screening of innovative immune-oncology compounds..

通过与Cypre的合作，Charles River的客户可以访问Cypre的3D肿瘤模型，以在精确的肿瘤微环境模型中预测治疗效果和作用机制。利用Cypre的专利3D水凝胶技术和专有方法，结合Charles River的PDX肿瘤模型库，该平台重现了肿瘤微环境，并能够对创新的免疫肿瘤化合物进行预测性筛选。

Humanized Models

人源化模型

Charles River offers a comprehensive line of humanized mice models to support researchers in replicating human immune interactions and therapeutics responses in controlled, in vivo environments. Charles River has expanded its offering of humanized mouse models by introducing two new PBMC models that reduce the onset of graft versus host disease (GvHD).

查尔斯河提供全面的人源化小鼠模型系列，以支持研究人员在可控的体内环境中复制人类免疫相互作用和治疗反应。查尔斯河通过引入两种新的PBMC模型（减少移植物抗宿主病（GvHD）的发生），扩展了其人源化小鼠模型的产品线。

Along those lines, the Company offers a PBMC Select Humanization Kit, giving researchers the ability to leverage pre-qualified PMBCs and engraft specific NCG mice for improved study flexibility..

基于这些方面，公司提供了一种PBMC选择性人源化试剂盒，使研究人员能够利用预先鉴定合格的PBMC，并移植特定的NCG小鼠，从而提高研究的灵活性。

Eva Oswald is presenting on a PDX biobank in humanized mice and Steve Bronson is presenting on PMBC-humanized, MHC-deficient NCG mice that support human tumor xenographs without rapid onset GvHD, both beginning on Monday, April 28, 2025, at 9:00 a.m.

伊娃·奥斯瓦尔德将介绍人源化小鼠中的PDX生物样本库，史蒂夫·布隆森将介绍支持人类肿瘤异种移植且不会迅速引发GvHD的PMBC人源化、MHC缺陷型NCG小鼠。两人均将于2025年4月28日星期一上午9:00开始报告。

Leveraging AI in Oncology

利用人工智能在肿瘤学领域

The influence of artificial intelligence (AI) and machine learning (ML) tools is beginning to impact how researchers analyze cancer research data. Charles River recently collaborated with Revvity, Inc., to determine the feasibility of automatic organ volumetric analysis from 3D ultrasound images of mice using deep learning.

人工智能（AI）和机器学习（ML）工具的影响开始改变研究人员分析癌症研究数据的方式。查尔斯河实验室近期与Revvity公司合作，利用深度学习技术，从老鼠的3D超声图像中进行自动器官体积分析，以验证其可行性。

Segmentation of 3D imaging data is labor intensive and measurements derived from human-annotated data are prone to inter-user variability and user error. To address these challenges, an AI model was generated to segment spleens from diverse 3D ultrasound images taken from several in vivo models..

三维成像数据的分割工作量大，且从人工标注数据中得出的测量结果容易受到用户间差异和用户错误的影响。为了解决这些挑战，生成了一个AI模型，用于从多种体内模型获取的多样化三维超声图像中分割脾脏。

David Harris is presenting on longitudinal ultrasound imaging as a novel pharmacodynamic marker of graft versus host disease progression in mice with Revvity on Monday, April 28, 2025, at 2:00 p.m.

大卫·哈里斯将于2025年4月28日星期一下午2点与Revvity一起展示纵向超声成像作为小鼠移植物抗宿主病进展的新型药效学标志物。

Charles River is also partnering with Aitia to develop virtual control groups (VCGs) supported by Charles River’s extensive and well-categorized library of PDX data. VCGs, combined with insights from PDXs, allow researchers to predict tumor evolution over time in a specific model, reducing the need for control animals in future experiments and supporting the principles of the 3Rs (Replacement, Reduction, and Refinement)..

查尔斯河还与Aitia合作，利用查尔斯河广泛且分类清晰的PDX数据图书馆来开发虚拟对照组（VCG）。结合PDX的见解，VCG可以预测特定模型中肿瘤随时间的演变，减少未来实验对对照动物的需求，并支持3R原则（替代、减少和优化）。

Global Support for the RACE Act

全球支持RACE法案

As part of our broad oncology portfolio, Charles River, via the ITCC-P4 consortium, offers over 200 annotated, well-characterized, and Research to Accelerate Cures and Equity (RACE) for Children Act-compliant pediatric PDX models to accelerate time to clinic. These are critical models for research, as the U.S.

作为我们广泛的肿瘤学产品组合的一部分，Charles River通过ITCC-P4联盟，提供了200多个注释清晰、特性明确且符合《加速治愈与公平法案》（RACE for Children Act）的儿童PDX模型，以加快临床应用的时间。这些模型对研究至关重要，因为美国...

Food and Drug Administration’s RACE Act requires nearly all oncology drugs to be tested for pediatric indications before approval..

美国食品药品监督管理局的RACE法案要求几乎所有肿瘤学药物在批准前都必须测试其儿科适应症。

“Globally, 400,000 children and adolescents develop cancer each year, and approximately one in four cannot be cured with currently available therapies,” added Schueler. “Combined with our comprehensive portfolio of oncology drug discovery and development services, we are positioned to assess the safety and efficacy of new oncology treatments, specifically in this critically important patient population.”.

“全球每年有40万名儿童和青少年罹患癌症，其中大约四分之一的患者无法通过目前可用的疗法治愈，”舒勒补充道。“结合我们在肿瘤药物发现和开发服务方面的综合业务组合，我们有能力评估新型肿瘤治疗方案的安全性和有效性，特别是在这个至关重要的患者群体中。”

Charles River is proud to sponsor the Richi Childhood Cancer Foundation at AACR 2025. Attendees can stop at Booth #1642 to learn how to actively support the mission to connect, support, and uplift children, youth with cancer, and survivors through the Richi House.

查尔斯河很荣幸在2025年AACR会议上赞助里奇儿童癌症基金会。与会者可以前往1642号展位，了解如何通过里奇之家积极支持连接、帮助和鼓舞患有癌症的儿童、青少年及幸存者的使命。

AACR Annual Meeting 2025: Transforming Oncology Drug Development

AACR年会2025：变革肿瘤药物开发

Charles River’s team has the capability to optimize workflows and maximize success across modalities including small and large molecules, cell and gene therapies, vaccines, and combination therapies. Charles River also recently launched an alliance with NJ Bio to optimize the development and manufacturing of antibody drug conjugates (ADCs.).

查尔斯河的团队有能力优化工作流程，并在包括小分子和大分子、细胞和基因疗法、疫苗以及组合疗法等多种模式中取得最大成功。查尔斯河最近还与NJ Bio建立了联盟，以优化抗体药物偶联物（ADCs）的开发和生产。

During the show, Charles River is presenting a Spotlight on HER2 therapy development on Monday, April 28, 2025 from 3:00-4:00 p.m. Visit Charles River during AACR at Booth #1642 during the show, and visit criver.com to schedule a meeting, view a full schedule of activities, and explore oncology resources..

在展会期间，查尔斯河将于2025年4月28日星期一下午3:00-4:00举办关于HER2治疗开发的专题亮点活动。在AACR展会期间，请前往查尔斯河展位（#1642），并访问criver.com安排会议、查看完整的活动日程，并探索肿瘤学资源。

About Charles River

关于查尔斯河

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them.

查尔斯河提供关键的产品和服务，帮助全球制药和生物技术公司、政府机构以及领先的学术机构加快研究和药物开发进程。我们敬业的员工专注于为客户提供他们所需的一切，以改进和加速新疗法的发现、早期开发及安全制造，从而惠及需要这些疗法的患者。

To learn more about our unique portfolio and breadth of services, visit www.criver.com..

要了解更多关于我们独特的投资组合和广泛的服务，请访问 www.criver.com。

Charles River Investor Contact:

查尔斯河投资者联系人：

Todd Spencer

托德·斯宾塞

Corporate Vice President,

公司副总裁，

Investor Relations

投资者关系

781.222.6455